ATE475668T1 - Immunisierung durch impfung von dns transkriptionseinheit - Google Patents

Immunisierung durch impfung von dns transkriptionseinheit

Info

Publication number
ATE475668T1
ATE475668T1 AT01202355T AT01202355T ATE475668T1 AT E475668 T1 ATE475668 T1 AT E475668T1 AT 01202355 T AT01202355 T AT 01202355T AT 01202355 T AT01202355 T AT 01202355T AT E475668 T1 ATE475668 T1 AT E475668T1
Authority
AT
Austria
Prior art keywords
vertebrate
transcription unit
dna transcription
cell
humoral
Prior art date
Application number
AT01202355T
Other languages
English (en)
Inventor
Harriet L Robinson
Ellen F Fynan
Robert G Webster
Shan Lu
Original Assignee
Univ Massachusetts Medical
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/187,879 external-priority patent/US6841381B1/en
Application filed by Univ Massachusetts Medical, St Jude Childrens Res Hospital filed Critical Univ Massachusetts Medical
Application granted granted Critical
Publication of ATE475668T1 publication Critical patent/ATE475668T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01202355T 1994-01-27 1995-01-25 Immunisierung durch impfung von dns transkriptionseinheit ATE475668T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/187,879 US6841381B1 (en) 1992-03-23 1994-01-27 Immunization by inoculation of DNA transcription unit

Publications (1)

Publication Number Publication Date
ATE475668T1 true ATE475668T1 (de) 2010-08-15

Family

ID=22690873

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01202355T ATE475668T1 (de) 1994-01-27 1995-01-25 Immunisierung durch impfung von dns transkriptionseinheit

Country Status (7)

Country Link
EP (2) EP0740704A1 (de)
JP (2) JP4050310B2 (de)
AT (1) ATE475668T1 (de)
CA (1) CA2181832C (de)
DE (1) DE69536091D1 (de)
ES (1) ES2348013T3 (de)
WO (1) WO1995020660A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US6165993A (en) * 1992-03-23 2000-12-26 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
GB9709900D0 (en) * 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
WO1997017063A1 (en) * 1995-11-09 1997-05-15 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
WO1997028265A1 (en) * 1996-02-05 1997-08-07 University Of Massachusetts Medical Center Measles immunization by dna transcription unit inoculation
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
ATE309366T1 (de) * 1996-02-22 2005-11-15 Merck & Co Inc Synthetische hiv-gene
WO1997048370A2 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
WO1998000554A1 (en) 1996-07-03 1998-01-08 Genetics Institute, Inc. Protease fmh-1, an ice/ced-like protease
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US7294338B2 (en) 1996-07-19 2007-11-13 Merial Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751224B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
CN1044092C (zh) 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
EP1096957A1 (de) 1998-06-18 2001-05-09 Johns Hopkins University School of Medicine Verfahren und reagentien zur intramuskulären zufuhr von nukleinsäuren
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
WO2000047227A2 (en) 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US6783759B2 (en) 2002-03-27 2004-08-31 Trustees Of The University Of Pennsylvania Compositions and methods for modulating variola virus
US6982156B2 (en) 2002-03-27 2006-01-03 Trustees Of The University Of Pennsylvania Compositions and methods modulating variola and vaccinia virus
EA010056B1 (ru) 2003-10-10 2008-06-30 Паудерджект Вэксинс, Инк. Конструкции нуклеиновых кислот
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
US7342107B2 (en) 2004-05-27 2008-03-11 Centocor, Inc. Cynomolgus prostate specific antigen
US20060121031A1 (en) 2004-12-07 2006-06-08 Mckenzie Brent S Relay vaccine
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
BRPI0812346B1 (pt) 2007-06-08 2019-01-22 Australian Poultry Crc Pty Ltd célula hospedeira, método para a produção de um polipeptídeo isolado, composição, vacinas, método de atenuação da virulência de uma bactéria, método para determinar se um indivíduo foi exposto a um patógeno e uso da célula hospedeira, das vacinas ou da bactéria
CN101970491A (zh) 2007-08-30 2011-02-09 沃尔特及伊莱萨霍尔医学研究院 树突状细胞标记物及其用途
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
JP6096111B2 (ja) 2010-05-10 2017-03-15 アセンド・バイオファーマシューティカルズ・リミテッド 免疫刺激組成物及びワクチン組成物
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
CN112316129B (zh) 2014-04-03 2025-01-28 勃林格殷格翰动物保健美国有限公司 猪流行性腹泻病毒疫苗
AU2015283805B2 (en) 2014-06-30 2021-02-25 Murdoch Childrens Research Institute Helicobacter therapeutic
US9920302B2 (en) 2015-08-31 2018-03-20 Boehringer Ingelheim Vetmedica Gmbh Pestivirus vaccines for congenital tremors
CA2996613A1 (en) 2015-09-16 2017-03-23 Boehringer Ingelheim Vetmedica, Inc. Salmonella choleraesuis-salmonella typhimurium vaccines
AU2017332677B2 (en) 2016-09-20 2024-01-11 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
DK3516064T3 (da) 2016-09-20 2025-07-14 Boehringer Ingelheim Vetmedica Gmbh Nye promotorer
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
AR109538A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra la gripe porcina
EA201991065A1 (ru) 2016-11-03 2019-11-29 Вакцина против свиного парвовируса
AU2017353380B2 (en) 2016-11-03 2024-08-22 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
EP3573655A2 (de) 2017-01-30 2019-12-04 Boehringer Ingelheim Animal Health USA Inc. Impfstoffe gegen porzines coronavirus
EP3651797A1 (de) 2017-07-12 2020-05-20 Boehringer Ingelheim Animal Health USA Inc. Immunogene senecavirus-a-zusammensetzungen und verfahren dafür
KR20200057742A (ko) 2017-09-23 2020-05-26 베링거잉겔하임베트메디카게엠베하 파라믹소바이러스과 발현 시스템
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
CN111712575B (zh) 2018-02-23 2024-07-19 勃林格殷格翰动物保健有限公司 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
AR115002A1 (es) 2018-03-19 2020-11-18 Boehringer Ingelheim Vetmedica Gmbh Ehv con ul18 y/o ul8 inactivados
JP7245260B2 (ja) 2018-03-19 2023-03-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｅｈｖ挿入部位ｕｌ４３
KR20260008832A (ko) 2018-03-26 2026-01-16 베링거 인겔하임 애니멀 헬스 유에스에이 인크. 면역원성 조성물의 제조방법
TW202027785A (zh) 2018-09-20 2020-08-01 德商百靈佳殷格翰維美迪加股份有限公司 經修飾之pedv棘蛋白
TW202026010A (zh) 2018-09-20 2020-07-16 德商百靈佳殷格翰維美迪加股份有限公司 抗豬流行性下痢之鼻內載體疫苗
US11858962B2 (en) 2020-02-06 2024-01-02 Boehringer Ingelheim Vetmedica Gmbh Polypeptides useful for detecting anti-rhabdovirus antibodies
WO2022076977A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
JP2023544396A (ja) 2020-10-05 2023-10-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ロタウイルスに対するワクチン接種のために有用な融合タンパク質
WO2023194913A1 (en) 2022-04-05 2023-10-12 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626288B2 (en) * 1988-02-05 1992-07-30 Commonwealth Scientific And Industrial Research Organisation Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence
EP0737750B1 (de) * 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
MX9300883A (es) * 1992-02-18 1994-08-31 Smithkline Beecham Corp Polipeptidos de vacuna.
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CA2102918C (en) 1992-03-11 2007-05-08 Joel R. Haynes Genetic vaccine for immunodeficiency viruses
WO1993025235A1 (en) 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides

Also Published As

Publication number Publication date
JP4050310B2 (ja) 2008-02-20
EP1170368A2 (de) 2002-01-09
DE69536091D1 (de) 2010-09-09
EP1170368A3 (de) 2004-05-12
CA2181832A1 (en) 1995-08-03
EP1170368B1 (de) 2010-07-28
CA2181832C (en) 2012-11-27
ES2348013T3 (es) 2010-11-26
WO1995020660A3 (en) 1995-12-21
JP2006316072A (ja) 2006-11-24
JPH09508622A (ja) 1997-09-02
WO1995020660A2 (en) 1995-08-03
EP0740704A1 (de) 1996-11-06

Similar Documents

Publication Publication Date Title
DE69536091D1 (de) Immunisierung durch Impfung von DNS Transkriptionseinheit
CA2132836A1 (en) Immunization by inoculation of dna transcription unit
FI953608A7 (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalv ossa järjestelmällisellä rokottamisella
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
WO2000020027A3 (en) Methods for therapeutic vaccination
EP1162272B8 (de) Herstellung von einer Immunantwort gegen Prostat-spezifisches Antigen (PSA)
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
ATE292641T1 (de) Mucin-mannan-konjugate und ihre immunotherapeutische anwendung
ATE318899T1 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
NO954318D0 (no) Immunogent preparat av OspC-antigenvaksiner for forhindring og behandling av Lymesykdom, samt rekombinante fremgangsmåter for fremstilling av slike antigener
ATE149569T1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
ATE206138T1 (de) Helicobacter pylori antigen
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
EP1502602A3 (de) Verfahren zur therapeutischen Impfung
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
DK0623170T3 (da) Vacciner baseret på streptokinase
DK1913957T3 (da) Genetiske adjuvant-vacciner
WO2002085409A3 (en) Methods and compositions for inducing an immune response to an antigen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties